Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Identifying safe long term investments is essential for risk-averse investors. Learn about reliable options to secure your financial future.
26,844 articlesCRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
ADA sinks toward its latest lows as the broader crypto sell-off deepens. With Hoskinson’s cautions and liquidity fadi...
Energy prices are pushing the stock market into a higher-volatility regime just as the CPI release looms. This guide ...
When a memory-stock rally hits the headlines, you want the real story behind the move. This guide explains why sandis...
Kyntra Bio (KYNB) is on investors' radar as 2025 earnings wrap up. This guide breaks down what the Q4 results mean, h...
Nokia’s latest move isn't about handsets—it's about AI-friendly data-center networks. The Nokia acquired Infinera qui...
VR Adviser recently disclosed a substantial sale of Ocular Therapeutix shares, triggering questions about what it mea...
As AI chip fears rattled markets, microsoft stock rose today thanks to cloud momentum, AI software adoption, and stro...
The Trade Desk slid again amid reports of agency cautions and analyst downgrades. This piece explains the drivers, wh...
Prices stay higher than a few years ago, eroding cash savings. A trio of ETFs—GLD, VTIP, and DBC—are positioned to he...
Investors are weighing a shift from high-growth tech to more income-driven energy plays as AI-era capex creates uncer...